Antikörpertherapie beim metastasierten kolorektalen Karzinom - was der Chirurg wissen sollte

Zusammenfassung

Fortschritte in der medikamentösen Therapie des kolorektalen Karzinoms haben in den letzten Jahren durch die Einführung neuer zytotoxischer Präparate zu einer signifikanten Verbesserung der Behandlung von betroffenen Patienten geführt. Neue Erkenntnisse in der molekularen Tumorbiologie führten zusätzlich zur Entwicklung einer Reihe von zielgerichteten, tumorspezifischen monoklonalen Antikörpern, die sich nun in verschiedenen Stadien der klinischen Erprobung befinden. Zwei dieser Antikörper, Cetuximab (Erbitux®) und Bevacizumab (Avastin®), gerichtet gegen den Epidermal Growth Factor Receptor (EGFR) bzw. den Vascular Epithelial Growth Factor (VEGF), wurden in der Zwischenzeit für die Behandlung des metastasierten kolorektalen Karzinoms zugelassen. Die Kombination von altbekannten und neuentwickelten Zytostatika mit monoklonalen Antikörpern hat die medikamentöse Behandlung des kolorektalen Karzinoms zwar wesentlich komplexer gemacht, bietet aber gerade Patienten mit Metastasen einen zusätzlichen Therapieansatz.

Abstract

Advances in the medical treatment of colorectal cancer patients have resulted in considerable improvements through the introduction of new cytotoxic drugs. The significant progress in molecular and tumour biology has produced a great number of targeted, tumour-specific, monoclonal antibodies that are now in various stages of clinical development. Two of these antibodies, cetuximab (Erbitux®) und bevacizumab (Avastin®), directed against the epidermal growth factor receptor (EGFR) and the vascular epithelial growth factor (VEGF), respectively, have recently been approved for use in metastatic colorectal cancer. The combination of well-known and newly developed cytotoxic agents with monoclonal antibodies makes the medical treatment of colorectal cancer patients considerably more complex, but also provides additional therapeutic strategies for patients in advanced stages of disease.

zielgerichtete Therapie - kolorektales Karzinom - EGFR - VEGF

targeted therapy - colorectal cancer - EGFR - VEGF

Literatur

• 1 Akbulut H, Altuntas F, Akbulut K G, Ozturk G, Cindoruk M, Unal E, Icli F. Prognostic role of serum vascular endothelial growth factor, basic fibroblast growth factor and nitric oxide in patients with colorectal carcinoma.  Cytokine. 2002;  20 184-190
• 2 Baselga J. The EGFR as a target for anticancer therapy - focus on cetuximab.  Eur J Cancer. 2001;  37 Suppl 4 S16-S22
• 3 Chaudhary V K, Fitzgerald D J, Adhya S, Pastan I. Activity of a recombinant fusion protein between transforming growth factor type alpha and Pseudomonas toxin.  Proc Natl Acad Sci USA. 1987;  84 4538-4542
• 4 Ciardiello F, Caputo R, Troiani T, Borriello G, Kandimalla E R, Agrawal S, Mendelsohn J, Bianco A R, Tortora G. Antisense oligonucleotides targeting the epidermal growth factor receptor inhibit proliferation, induce apoptosis, and cooperate with cytotoxic drugs in human cancer cell lines.  Int J Cancer. 2001;  93 172-178
• 5 Cunningham D, Humblet Y, Siena S, Khayat D, Bleiberg H, Santoro A, Bets D, Mueser M, Harstrick A, Verslype C, Chau I, Van Cutsem E. Cetuximab monotherapy and cetuximab plus irinotecan in irinotecan-refractory metastatic colorectal cancer.  N Engl J Med. 2004;  351 337-345
• 6 de Gramont A, Bosset J F, Milan C, Rougier P, Bouche O, Etienne P L, Morvan F, Louvet C, Guillot T, Francois E, Bedenne L. Randomized trial comparing monthly low-dose leucovorin and fluorouracil bolus with bimonthly high-dose leucovorin and fluorouracil bolus plus continuous infusion for advanced colorectal cancer: a French intergroup study.  J Clin Oncol. 1997;  15 808-815
• 7 Ellerbroek S M, Halbleib J M, Benavidez M, Warmka J K, Wattenberg E V, Stack M S, Hudson L G. Phosphatidylinositol 3-kinase activity in epidermal growth factor-stimulated matrix metalloproteinase-9 production and cell surface association.  Cancer Res. 2001;  61 1855-1861
• 8 Fan Z, Lu Y, Wu X, Mendelsohn J. Antibody-induced epidermal growth factor receptor dimerization mediates inhibition of autocrine proliferation of A 431 squamous carcinoma cells.  J Biol Chem. 1994;  269 27595-27602
• 9 Ferrara N, Gerber H P, LeCouter J. The biology of VEGF and its receptors.  Nat Med. 2003;  9 669-676
• 10 Folkman J. Angiogenesis in cancer, vascular, rheumatoid and other disease.  Nat Med. 1995;  1 27-31
• 11 Gordon M S, Cunningham D. Managing patients treated with bevacizumab combination therapy.  Oncology. 2005;  69 Suppl 3 25-33
• 12 Gordon M S, Margolin K, Talpaz M, Sledge Jr G W, Holmgren E, Benjamin R, Stalter S, Shak S, Adelman D. Phase I safety and pharmacokinetic study of recombinant human anti-vascular endothelial growth factor in patients with advanced cancer.  J Clin Oncol. 2001;  19 843-850
• 13 Gross M E, Zorbas M A, Danels Y J, Garcia R, Gallick G E, Olive M, Brattain M G, Boman B M, Yeoman L C. Cellular growth response to epidermal growth factor in colon carcinoma cells with an amplified epidermal growth factor receptor derived from a familial adenomatous polyposis patient.  Cancer Res. 1991;  51 1452-1459
• 14 Grothey A, Sargent D, Goldberg R M, Schmoll H J. Survival of patients with advanced colorectal cancer improves with the availability of fluorouracil-leucovorin, irinotecan, and oxaliplatin in the course of treatment.  J Clin Oncol. 2004;  22 1209-1214
• 15 Heinzerling J H, Huerta S. Bowel perforation from Bevacizumab for the treatment of metastatic colon cancer: incidence, etiology, and management.  Curr Surg. 2006;  63 334-337
• 16 Hochster H S, Hart L L, Ramanathan R K, Hainsworth J D, Hedrick I I, Childs B H. Safety and efficacy of oxaliplatin / fluoropyrimidine regimens with or without bevacizumab as first-line treatment of metastatic colorectal cancer: final analysis of the TREE-study.  J Clin Oncol. 2006;  24 3510 ,  ASCO Annual Meeting Proceedings Part I Vol 24 No 18 S (June 20 supplement)
• 17 Hurwitz H, Fehrenbacher L, Novotny W, Cartwright T, Hainsworth J, Heim W, Berlin J, Baron A, Griffing S, Holmgren E, Ferrara N, Fyfe G, Rogers B, Ross R, Kabbinavar F. Bevacizumab plus irinotecan, fluorouracil, and leucovorin for metastatic colorectal cancer.  N Engl J Med. 2004;  350 2335-2342
• 18 Italiano A. Targeting the epidermal growth factor receptor in colorectal cancer: advances and controversies.  Oncology. 2006;  70 161-167
• 19 Kabbinavar F, Hurwitz H I, Fehrenbacher L, Meropol N J, Novotny W F, Lieberman G, Griffing S, Bergsland E. Phase II, randomized trial comparing bevacizumab plus fluorouracil (FU) / leucovorin (LV) with FU / LV alone in patients with metastatic colorectal cancer.  J Clin Oncol. 2003;  21 60-65
• 20 Kang S M, Maeda K, Onoda N, Chung Y S, Nakata B, Nishiguchi Y, Sowa M. Combined analysis of p53 and vascular endothelial growth factor expression in colorectal carcinoma for determination of tumor vascularity and liver metastasis.  Int J Cancer. 1997;  74 502-507
• 21 Khorana A A, Ryan C K, Cox C, Eberly S, Sahasrabudhe D M. Vascular endothelial growth factor, CD 68, and epidermal growth factor receptor expression and survival in patients with Stage II and Stage III colon carcinoma: a role for the host response in prognosis.  Cancer. 2003;  97 960-968
• 22 Koenders P G, Peters W H, Wobbes T, Beex L V, Nagengast F M, Benraad T J. Epidermal growth factor receptor levels are lower in carcinomatous than in normal colorectal tissue.  Br J Cancer. 1992;  65 189-192
• 23 Kohne C H, Folprecht G. Current perspectives in the treatment of metastatic colorectal cancer.  Ann Oncol. 2004;  15 Suppl 4 iv 43-iv 53
• 24 Lee J C, Chow N H, Wang S T, Huang S M. Prognostic value of vascular endothelial growth factor expression in colorectal cancer patients.  Eur J Cancer. 2000;  36 748-753
• 25 Lin Y S, Nguyen C, Mendoza J L, Escandon E, Fei D, Meng Y G, Modi N B. Preclinical pharmacokinetics, interspecies scaling, and tissue distribution of a humanized monoclonal antibody against vascular endothelial growth factor.  J Pharmacol Exp Ther. 1999;  288 371-378
• 26 Lockhart A C, Berlin J D. The epidermal growth factor receptor as a target for colorectal cancer therapy.  Semin Oncol. 2005;  32 52-60
• 27 McKay J A, Murray L J, Curran S, Ross V G, Clark C, Murray G I, Cassidy J, McLeod H L. Evaluation of the epidermal growth factor receptor (EGFR) in colorectal tumours and lymph node metastases.  Eur J Cancer. 2002;  38 2258-2264
• 28 Mendelsohn J, Baselga J. Status of epidermal growth factor receptor antagonists in the biology and treatment of cancer.  J Clin Oncol. 2003;  21 2787-2799
• 29 Meropol N J, Berlin J D, Hecht J R, Croghan G A, Patnaik A, Weiner L M, Sweed M, Wiens B L, Caron D, Visonneau S. Multicenter study of ABX-EGF monotherapy in patients with metastatic colorectal cancer.  Proc Am Soc Clin Oncol. 2003;  22 (abstr 1026)
• 30 National Institute for Health and Clinical Excellence .Final appraisal determination, Bevacizumab and cetuximab for metastatic colorectal cancer.  www.nice.org.uk 2006
• 31 Ozawa S, Ueda M, Ando N, Abe O, Minoshima S, Shimizu N. Selective killing of squamous carcinoma cells by an immunotoxin that recognizes the EGF receptor.  Int J Cancer. 1989;  43 152-157
• 32 Peeters M, Van Cutsem E, Siena S, Humblet Y, Hendlisz A, Neyns J, Canon J, Van Laethem M, Amado R. A phase 3, multicenter, randomized controlled trial of panitumumab plus best supportive care (BSC) vs. BSC alone in patients with metastatic colorectal cancer.  Proc Am Soc Clin Oncol. 2006;  abstr 3548
• 33 Perrotte P, Matsumoto T, Inoue K, Kuniyasu H, Eve B Y, Hicklin D J, Radinsky R, Dinney C P. Anti-epidermal growth factor receptor antibody C 225 inhibits angiogenesis in human transitional cell carcinoma growing orthotopically in nude mice.  Clin Cancer Res. 1999;  5 257-265
• 34 Prewett M C, Hooper A T, Bassi R, Ellis L M, Waksal H W, Hicklin D J. Enhanced antitumor activity of anti-epidermal growth factor receptor monoclonal antibody IMC-C 225 in combination with irinotecan (CPT-11) against human colorectal tumor xenografts.  Clin Cancer Res. 2002;  8 994-1003
• 35 Radinsky R, Risin S, Fan D, Dong Z, Bielenberg D, Bucana C D, Fidler I J. Level and function of epidermal growth factor receptor predict the metastatic potential of human colon carcinoma cells.  Clin Cancer Res. 1995;  1 19-31
• 36 Raymond E, Faivre S, Armand J P. Epidermal growth factor receptor tyrosine kinase as a target for anticancer therapy.  Drugs. 2000;  60 Suppl 1 15-23
• 37 Rougier P, Raoul J VLM, Mueser M. Cetuximab and FOLFIRI as first-line treatment for metastatic colorectal CA.  J Clin Oncol. 2004;  22 3 , ASCO Annual Meeting Proceedings (Post-Meeting Edition). Vol 22, No 145 (July 15 Supplement), 2004: 3
• 38 Roy H, Bhardwaj S, Yla-Herttuala S. Biology of vascular endothelial growth factors.  FEBS Lett. 2006;  580 2879-2887
• 39 Saltz L B, Meropol N J, Loehrer Sr P J, Needle M N, Kopit J, Mayer R J. Phase II trial of cetuximab in patients with refractory colorectal cancer that expresses the epidermal growth factor receptor.  J Clin Oncol. 2004;  22 1201-1208
• 40 Tabernero J, Van Cutsem E, Sastre J, Cervantes A, Mueser M. An international phase II study of cetuximab in combination with oxaliplatin / 5-FU / folinic acid (FOLFOX 4) in the first-line treatment of patients with metastatic colorectal cancer expressing Epidermal Growth Factor Receptor. Preliminary results.  J Clin Oncol. 2004;  22 39 ,  ASCO Annual Meeting Proceedings (Post Meeting Edition) Vol 22, No 145 (July 15 Supplement), 2004: 39
• 41 Takahashi Y, Kitadai Y, Bucana C D, Cleary K R, Ellis L M. Expression of vascular endothelial growth factor and its receptor, KDR, correlates with vascularity, metastasis, and proliferation of human colon cancer.  Cancer Res. 1995;  55 3964-3968
• 42 Thirion P, Michiels S, Pignon J P, Buyse M, Braud A C, Carlson R W, O'Connell M, Sargent P, Piedbois P. Modulation of fluorouracil by leucovorin in patients with advanced colorectal cancer: an updated meta-analysis.  J Clin Oncol. 2004;  22 3766-3775
• 43 Tournigand C, Andre T, Achille E, Lledo G, Flesh M, Mery-Mignard D, Quinaux E, Couteau C, Buyse M, Ganem G, Landi B, Colin P, Louvet C, de Gramont A. FOLFIRI followed by FOLFOX6 or the reverse sequence in advanced colorectal cancer: a randomized GERCOR study.  J Clin Oncol. 2004;  22 229-237
• 44 Tyagi P. Vatalanib (PTK787 / ZK 222584) in combination with FOLFOX4 versus FOLFOX4 alone as first-line treatment for colorectal cancer: preliminary results from the CONFIRM-1 trial.  Clin Colorectal Cancer. 2005;  5 24-26
• 45 Warren R S, Yuan H, Matli M R, Gillett N A, Ferrara N. Regulation by vascular endothelial growth factor of human colon cancer tumorigenesis in a mouse model of experimental liver metastasis.  J Clin Invest. 1995;  95 1789-1797
• 46 Weiner L M. Updated results from a dose and schedule study of Panitumumab monotherapy in patients with advanced solid malignancies.  Proc Am Soc Clin Oncol. 2005;  abstr 3059
• 47 Wu X, Fan Z, Masui H, Rosen N, Mendelsohn J. Apoptosis induced by an anti-epidermal growth factor receptor monoclonal antibody in a human colorectal carcinoma cell line and its delay by insulin.  J Clin Invest. 1995;  95 1897-1905